A 28-week, prospective, single-arm, open label phase 4 study to evaluate treatment optimization with once-daily insulin glargine HOE901-300 IU/ml in combination with prandial rapid-acting insulin analogue in patients with type 1 diabetes previously uncontrolled on twice daily basal insulin as part of basal-bolus therapy

Trial Profile

A 28-week, prospective, single-arm, open label phase 4 study to evaluate treatment optimization with once-daily insulin glargine HOE901-300 IU/ml in combination with prandial rapid-acting insulin analogue in patients with type 1 diabetes previously uncontrolled on twice daily basal insulin as part of basal-bolus therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms OPTIMIZE
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Aug 2017 Planned number of patients changed from 102 to 90.
    • 29 Sep 2016 Planned number of patients changed from 119 to 102.
    • 15 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top